Usona Institute’s Psilocybin Receives the US FDA Breakthrough Therapy Designation for Major Depressive Disorder

 Usona Institute’s Psilocybin Receives the US FDA Breakthrough Therapy Designation for Major Depressive Disorder

Usona Institute’s Psilocybin Receives the US FDA Breakthrough Therapy Designation for Major Depressive Disorder

Shots:

  • The US FDA has granted the BT designation to psilocybin for promoting the efficient development of programs for psilocybin in MDD
  • The BT designation follows the launch of Usona’s P-II PSIL201 which includes ~80 patients at 7sites across the US. 2/7 study sites are recruiting while others are expected to be active by Q1’20
  • The BT designation to psilocybin targets the unmet medical need and the potential for improvement over existing therapies and foster Usona’s goal to advance the treatment paradigm toward new drug approval

Click here ­to­ read full press release/ article | Ref: Buisnesswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post